获取途径

作者

Tianbo Liu, Ling Yang, Yucheng Hou, Yu Tian, Milad Ashrafizadeh, Gorka Orive, Mingming Han, Yingnan Yang

作者单位

Affiliations ¹ Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, 150081, China. ² Pharmacy Department, Hunan University of Medicine General Hospital, Huaihua, China. ³ Key Laboratory of Brain and Cognitive Neuroscience, Research Center of Brain and Cognitive Neuroscience, Liaoning Normal University, Dalian, China. ⁴ Hepato-Pancreato-Biliary Center, Beijing Tsinghua Changgung Hospital, Key Laboratory of Digital Intelligence Hepatology (Ministry of Education, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, 102218, China. ⁵ Science Research Center, the Huizhou Central Peoples Hospital, Guangdong Medical University, Huizhou, Guangdong, China. ⁶ Department of Radiation Oncology, Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, China. ⁷ NanoBioCel Research Group, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain. gorka.orive@ehu.eus. ⁸ NanoBioCel Research Group Bioaraba,, Vitoria-Gasteiz, Spain. gorka.orive@ehu.eus. ⁹ Biomaterials and Nanomedicine (CIBER-BBN), Biomedical Research Networking Centre in Bioengineering, Vitoria-Gasteiz, Spain. gorka.orive@ehu.eus. ¹⁰ University Institute for Regenerative Medicine and Oral Implantology, UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria, 01007, Spain. gorka.orive@ehu.eus. ¹¹ Department of Pharmacy and Medical Devices, Shandong Academy of Occupational Health and Occupational Medicine, Occupational Disease Hospital of Shandong First Medical University (Shandong Province Hospital Occupational Disease Hospital), Jinan, Shandong, China. 15806627767@16 com. ¹² Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, China. yangyingnanltx@16 com.

刊名

Journal of nanobiotechnology

年份

2025

卷号

Vol.23 No.1

页码

671

ISSN

1477-3155

关键词

Cancer immunotherapy Immunogenic cell death Photocatalytic nanoparticles Spatiotemporal drug delivery Tumor microenvironment.

摘要

In spite of the introduction of cancer immunotherapy for improving tumor suppression, the modality of this revolutionary treatment has faced a number of challenges because of immune evasion, poor tumor immunogenicity, and resistance in solid tumors. To address these challenges, immuno-photocatalytic nanoparticles have been engineered to enable spatiotemporal activation of antitumor immunity by integrating phototherapy with immune modulation. These multifunctional nanoplatforms utilize photo- or ...更多

In spite of the introduction of cancer immunotherapy for improving tumor suppression, the modality of this revolutionary treatment has faced a number of challenges because of immune evasion, poor tumor immunogenicity, and resistance in solid tumors. To address these challenges, immuno-photocatalytic nanoparticles have been engineered to enable spatiotemporal activation of antitumor immunity by integrating phototherapy with immune modulation. These multifunctional nanoplatforms utilize photo- or ultrasound-responsive cores to generate reactive oxygen species , stimulate immunogenic cell death and enhance the release of tumor-associated antigens. Simultaneously, these platforms allow for the co-delivery of immune checkpoint inhibitors and adjuvants to remodel the tumor microenvironment , enhance dendritic cell maturation, and stimulate cytotoxic T lymphocyte activation. Advanced materials, such as titanium dioxide, copper sulfide, and manganese-based nanostructures, are functionalized with targeting ligands, biodegradable coatings, and diagnostic agents to improve selectivity, circulation time, and imaging capabilities. These nanoparticles also utilize tumor-specific features, such as acidic pH and hypoxia, to trigger controlled drug release and activate various synergistic pathways such as pyroptosis, ferroptosis, and cuproptosis. Preclinical models have shown their substantial effects on tumor suppression, immune activation, and prevention of metastasis with minimal systemic toxicity. Clinically, these nanoplatforms possess a significant potential in overcoming current therapeutic barriers to enable the minimally invasive and highly specific treatment of immunologically resistant tumors. Clinical translation depends on a number of factors including biosafety, large-scale production and regulatory compliance. Immuno-photocatalytic nanomedicine represents a versatile, programmable approach that can be adopted to advance personalized long-term cancer immunotherapy.收起

文献类型

期刊